Radiotherapy/Chemoradiotherapy for Geriatric Head and Neck Cancer Patients

Year 2023, Volume: 2 Issue: 5, 266 - 274, 27.12.2023

Çağkan Ergiden

https://doi.org/10.5505/achmedj.2023.66375

Abstract

Introductıon: In our study, it was aimed to analyze radiotherapy (RT) compliance, acute toxicity results, and survival in geriatric patients with head and neck cancers.
Methods: In our study, 77 geriatric patients (≥ 70 years) underwent curative RT diagnosed with head and neck cancer between 04.05.2010 and 24.03.2022 in the Radiation Oncology Clinic of Ankara Bilkent City Hospital and Ankara Atatürk Training and Research Hospital were analyzed. The study’s primary outcome was RT completion, interruption, and acute adverse events. The study’s secondary endpoint was evaluating overall survival (OS) and progression-free survival (PFS).
Results: The median follow-up period of the study was 10 (range 1-130) months. The median age of the patients at the time of RT was 75 years. (Range 70-86). Most patients were diagnosed with laryngeal cancer (n=35, 45.5%). Of the 77 patients in our study, 71 (92.2%) completed their treatment, and 6 (7.8%) could not complete the radiotherapy course. Patients who could not complete the planned radiotherapy scheme were mostly diagnosed with laryngeal and hypopharyngeal cancer. (p=0.036; OR 1.94 95%CI 0.33-11.30). 71 patients completed treatment, and 67 (94.4%) did not interrupt treatment. In contrast, the treatment had to be interrupted for the last 4 (5.6%) patients. Grade 3 side effects were observed in 6 patients (7.8%). No grade 4 side effects were observed. During the follow-up period, 16 (20.8%) patients died; 61 (79.2%) were alive. Median OS was 9.8 (range 1 to 130) months. There was a significant relationship between OS and primary (p=0.035). Hypopharyngeal patients were significantly lower; nasopharyngeal and nasal cavity tumors have higher OS values. Local recurrence was observed in 6 (7.3%) of the patients and the median PFS was 8.9 (range 1-130) months.
Conclusion: In patients over 70 with head and neck cancer, definitive chemoradiotherapy (CRT) is a feasible treatment with acceptable toxicity.

Keywords

Geriatrics, Radiotherapy, Head and Neck Cancer

References

• 1. Hamaker ME, Te Molder M, Thielen N, van Munster BC, Schiphorst AH, van Huis LH. The effect of a geriatric evaluation on treatment decisions andoutcome for older cancer patients - A systematic review. J Geriatr Oncol 2018; 9(5): 430-40. 2. Jacobs JM, Maaravi Y, Cohen A, Bursztyn M, Ein-Mor E, Stessman J. Changing profile of health and function from age 70 to 85 years. Gerontology 2012 ;58(4) :313-21.
• 3. Müller von der Grün J, Martin D, Stöver T, Ghanaati S, Rödel C, Balermpas P. Chemoradiotherapy as Definitive Treatment for Elderly Patients with Head and Neck Cancer. Biomed Res Int 2018; 2018 :3508795.
• 4. Uslu GH, Serdar L, Aynacı Ö, Zengin A, Canyılmaz E. Evaluation of Prognostic Factors and Survival Results in Geriatric Patients with Head and Neck Cancer.
• 5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8. PMID: 31912902.
• 6. https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
• 7. Jelinek MJ, Howard AS, Haraf DJ, Vokes EE. Management of Early Head and Neck Cancer in Elderly Patients. J Oncol Pract 2018 ; 14(9) : 541-6.
• 8. Taylor MA, Switchenko J, Stokes W, Patel MR, McDonald M, Steuer C, Aiken A, Beitler JJ, Shin DM, Saba NF. Incidence trends of squamous cell carcinoma of the head and neck (SCCHN) in the aging population--A SEER-based analysis from 2000 to 2016. Cancer Med. 2021 Sep;10(17): 6070-6077. doi: 10.1002/cam4.4134. Epub 2021 Jul 20. PMID: 34288563; PMCID: PMC8419769
• 9. Chang S, Goldstein NE, Dharmarajan KV. Managing an Older Adult with Cancer: Considerations for Radiation Oncologists. Biomed Res Int. 2017; 2017: 1695101. doi: 10.1155/2017/1695101. Epub 2017 Dec 13. PMID: 29387715; PMCID: PMC5745659.
• 10. Sarini J, Fournier C, Lefebvre J, Bonafos G, Van JT, Coche-Dequéant B. Head and Neck Squamous Cell Carcinoma in Elderly Patients: A Long-term Retrospective Review of 273 Cases. Arch Otolaryngol Head Neck Surg. 2001; 127(9): 1089–1092. doi:10.1001/archotol.127.9.1089
• 11. Haehl E, Rühle A, David H, Kalckreuth T, Sprave T, Stoian R, Becker C, Knopf A, Grosu AL, Nicolay NH. Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly? Radiat Oncol. 2020 Feb 4; 15(1) :31. doi: 10.1186/s13014-020-1481-z. PMID: 32019576; PMCID: PMC7001207.
• 12. Bledsoe T.J., Noble A.R., Reddy C.A., Burkey B.B., Greskovich J.F., Nwizu T., Adelstein D.J., Saxton J.P., Koyfman S.A. Split-Course Accelerated Hypofractionated Radiotherapy (SCAHRT): A Safe and Effective Option for Head and Neck Cancer in the Elderly or Infirm. Anticancer Res. 2016; 36: 933–939
• 13. Benhmida S., Sun R., Gherga E., Hammoud Y., Rouvier J., Mauvais O., Bockel S., Louvrier A., Lebbad A., Bontemps P., et al. Split-course hypofractionated radiotherapy for aged and frail patients with head and neck cancers. A retrospective study of 75 cases. Cancer Radiother. 2020; 24: 812–819. doi: 10.1016/j.canrad.2020.03.013.
• 14. Stromberger C, Yedikat B, Coordes A, Tinhofer I, Kalinauskaite G, Budach V, Zschaeck S, Raguse JD, Kofla G, Heiland M, Stsefanenka A, Beck-Broichsitter B, Dommerich S, Senger C, Beck M. Prognostic Factors Predict Oncological Outcome in Older Patients With Head and Neck Cancer Undergoing Chemoradiation Treatment. Front Oncol. 2021 Feb 23; 10: 566318. doi: 10.3389 /fonc.2020.566318. PMID: 33708616; PMCID: PMC7942196.
• 15. Noor A, Gibb C, Boase S, Hodge JC, Krishnan S, Foreman A. Frailty in geriatric head and neck cancer: A contemporary review. Laryngoscope. 2018 Dec;128(12):E416-E424
• 16. Little MO. The Rapid Geriatric Assessment: A Quick Screen for Geriatric Syndromes. Mo Med. 2017 Mar-Apr; 114(2): 101-104. PMID: 30228554; PMCID: PMC6140035
• 17. Korc-Grodzicki B, Holmes HM, Shahrokni A. Geriatric assessment for oncologists. Cancer Biol Med. 2015 Dec; 12(4): 261-74. doi: 10.7497/j.issn.2095-3941.2015.0082. PMID: 26779363; PMCID: PMC4706523.
• 18. McAlister F, van Walraven C. External validation of the Hospital Frailty Risk Score and comparison with the Hospital-patient One-year Mortality Risk Score to predict outcomes in elderly hospitalised patients: a retrospective cohort study. BMJ Qual Saf. 2019 Apr; 28(4): 284-288. doi: 10.1136/bmjqs-2018-008661. Epub 2018 Oct 31. PMID: 30381331.
• 19. Al-mamgani A, Tans L, Van rooij PH, Noever I, Baatenburg de jong RJ, Levendag PC. Hypofractionated radiotherapy denoted as the "Christie scheme": an effective means of palliating patients with head and neck cancers not suitable for curative treatment. Acta Oncol. 2009; 48(4): 562-70. doi: 10.1080/02841860902740899. PMID: 19373698.
• 20. Piras A, Boldrini L, Menna S, Venuti V, Pernice G, Franzese C, Angileri T, Daidone A. Hypofractionated Radiotherapy in Head and Neck Cancer Elderly Patients: A Feasibility and Safety Systematic Review for the Clinician. Front Oncol. 2021 Nov 12; 11: 761393. doi: 10.3389/fonc.2021.761393. PMID: 34868976; PMCID: PMC8633531
• 21. Melo SM, Marta GN, Latorraca COC, Martins CB, Efthimiou O, Riera R. Hypofractionated radiotherapy for newly diagnosed elderly glioblastoma patients: A systematic review and network meta-analysis. PLoS One. 2021 Nov 4;16(11): e0257384. doi: 10.1371/journal.pone.0257384. PMID: 34735442; PMCID: PMC8568110.
• 22. Nair VJ, Caudrelier JM. Hypofractionated radiotherapy for elderly breast cancer patients: from early stages disease to local palliation for unresectable disease. Transl Cancer Res. 2020 Jan;9(Suppl 1): S189-S196. doi: 10.21037/tcr.2019.09.20. PMID: 35117962; PMCID: PMC8799247.
• 23. Fryen A, Brandes I, Wichmann J, Christiansen H, Tavassol F, Durisin M, Merten R. Moderately Hypofractionated Radiotherapy Without Chemotherapy in Elderly or Frail Patients With Head and Neck Cancer. In Vivo. 2022 May-Jun;36(3): 1259-1266. doi: 10.21873/invivo.12825. PMID: 35478110; PMCID: PMC9087067.
• 24. Dickstein DR, Lehrer EJ, Hsieh K, Hotca A, Jones BM, Powers A, Sharma S, Liu J, Gupta V, Mell L, Husain Z, Kirke D, Misiukiewicz K, Posner M, Genden E, Bakst RL. Management of Older Adults with Locally Advanced Head and Neck Cancer. Cancers (Basel). 2022 Jun 5;14(11):2809. doi: 10.3390/cancers14112809. PMID: 35681789; PMCID: PMC9179912.
• 25. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010 Jan;11(1): 21-8. doi: 10.1016/S1470-2045(09)70311-0. Epub 2009 Nov 10. Erratum in: Lancet Oncol. 2010 Jan;11(1):14. PMID: 19897418.
• 26. Michiels S, Le Maître A, Buyse M, et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: Meta-analyses of individual patient data. Lancet Oncol. 2009; 10: 341–350.
• 27. Gebre-Medhin M, Brun E, Engström P, Haugen Cange H, Hammarstedt-Nordenvall L, Reizenstein J, Nyman J, Abel E, Friesland S, Sjödin H, Carlsson H, Söderkvist K, Thomasson M, Zackrisson B, Nilsson P. ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients Wi th Locoregionally Advanced Head and Neck Squamous Cell Cancer. J Clin Oncol. 2021 Jan 1; 39(1): 38-47. doi: 10.1200/JCO.20.02072. Epub 2020 Oct 14. PMID: 33052757; PMCID: PMC7771720.
• 28. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma : RTOG 0522. J Clin Oncol. 2014 Sep 20; 32(27): 2940-50. doi: 10.1200/JCO.2013.53.5633. PMID: 25154822; PMCID: PMC4162493.
• 29. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, Jordan RCK, Zhao W, Sturgis EM, Burtness B, Ridge JA, Ringash J, Galvin J, Yao M, Koyfman SA, Blakaj DM, Razaq MA, Colevas AD, Beitler JJ, Jones CU, Dunlap NE, Seaward SA, Spencer S, Galloway TJ, Phan J, Dignam JJ, Le QT. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial . Lancet. 2019 Jan 5; 393(10166): 40-50. doi: 10.1016/S0140-6736(18)32779-X. Epub 2018 Nov 15. Erratum in: Lancet. 2020 Mar 7; 395(10226): 784. PMID: 30449625; PMCID: PMC6541928.
• 30. De Felice F, Vetrone L, Bulzonetti N, Caiazzo R, Marampon F, Musio D, Tombolini V. Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma. Med Oncol. 2019 Jun 12; 36(8): 68. doi: 10.1007/s12032-019-1292-y. PMID: 31190132.
• 31. Jang IJH, Skanthakumar T, Tan HK, Tan NC, Soo KC, Iyer NG. Elderly Patients with Advanced Head and Neck Carcinoma: Does Aggressive Treatment Result in Better Outcomes? Otolaryngology–Head and Neck Surgery. 2019; 160(4): 642-650. doi:10.1177/0194599818815065
• 32. Bese NS et al. Effects of prolongation of overall treatment time due to unplanned interruptions during radiotherapy of different tumor sites and practical methods for compensation . Int J Radiat Oncol Biol Phys. 2007; 68(3): 654–61.
• 33. Fasano M, D'Onofrio I, Belfiore MP, Angrisani A, Caliendo V, Della Corte CM, Pirozzi M, Facchini S, Caterino M, Guida C, Nardone V, Reginelli A, Cappabianca S. Head and Neck Squamous Cell Carcinoma in Elderly Patients: Role of Radiotherapy and Chemotherapy. Cancers (Basel). 2022 Jan 18; 14(3): 472. doi: 10.3390/cancers14030472. PMID: 35158740; PMCID: PMC8833743.
• 34. Jelinek MJ, Howard AS, Haraf DJ, Vokes EE. Management of Early Head and Neck Cancer in Elderly Patients. J Oncol Pract. 2018 Sep; 14(9): 541-546. doi: 10.1200/JOP.18.00078. PMID: 30285530.